News & Updates

Upadacitinib with topical corticosteroids shows good long-term efficacy and safety in patients with moderate-to-severe atopic dermatitis (AD), reports a recent follow-up analysis to the AD Up study.

Psoriasis patients treated with ixekizumab show better persistence and adherence over 24 months as well as a lower risk of discontinuation than those using secukinumab, reports a recent study that used real-world data.

Ustekinumab, a human monoclonal antibody that binds to the p40 subunit of both interleukin (IL)-12 and IL-23, demonstrates effectiveness and safety in the treatment of multiethnic Asian patients with moderate to severe plaque psoriasis, according to a Singapore study.

In patients with chronic spontaneous urticaria (CSU) who remained symptomatic despite treatment, the monoclonal anti-immunoglobulin E antibody ligelizumab improved symptom control regardless of BHRA* status, as well as dermatology quality of life (QoL) regardless of angioedema status, findings from a phase IIb study have shown.

Psoriasis patients, especially those with concomitant psoriatic arthritis (PsA), suffer from worse joint pain, leading to higher analgesic use rates than the general population, a recent study has found.

Difamilast ointment is superior to vehicle and can be a safe and effective option for the treatment of atopic dermatitis, a recent study reports.

In the phase II/III RELATIVITY-047 trial evaluating dual checkpoint inhibition for advanced melanoma, a new fixed-dose combination comprising the LAG-3 inhibitor relatlimab and the PD-1 inhibitor nivolumab fared better than nivolumab monotherapy.